Vistagen Therapeutics Inc (VTGN)

$0.55 -0.01 (-1.48%)
Market Cap 22.15M
Revenue (ttm) 490,000.00
Net Income (ttm) -51.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -10,493.88%
Debt to Equity Ratio 0.00
Volume 705,300
Avg Vol 3,247,128
Day's Range N/A - N/A
Shares Out 39.62M
Stochastic %K 70%
Beta 0.32
Analysts Hold
Price Target $0.97

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 577 3600
Address:
343 Allerton Avenue, South San Francisco, United States
Geo1313
Geo1313 Feb. 23 at 10:48 PM
$VTGN Because you are shorting it,thats what managment said.And also said that last time runned to$70 and burned losts of piuky shorts like you.
0 · Reply
CatchTheCleanUpSet
CatchTheCleanUpSet Feb. 23 at 7:43 PM
$VTGN so has management said anything about why the last trial failed ? And why 2 of the 3 trials failed but one did great ?
0 · Reply
smooth2222
smooth2222 Feb. 23 at 5:14 PM
$VTGN looks like .60 is our resistance.
1 · Reply
Geo1313
Geo1313 Feb. 23 at 7:25 AM
$VTGN Huge🚀🚀🚀
0 · Reply
Sinisoni
Sinisoni Feb. 23 at 12:51 AM
$VTGN bullish loading hard
1 · Reply
MakesHerSquirt
MakesHerSquirt Feb. 22 at 11:50 PM
$VTGN HAHA let's gamble ! 5x -10x! Who has the balls to play this high stakes game. THE HOUSE HAS THE ATVANTAGE!
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 21 at 3:49 PM
$VTGN
1 · Reply
mb0157
mb0157 Feb. 21 at 2:19 AM
$VTGN today’s news with Paul edick resignation is massive. He also dismissed his role at Xeris pharmacies Feb 1. No more conflict of interest. He’s known for creative deals so I can see two things possible. 1. Xers makes an all stock swap offer to Vtgn in March. $3-$4 range with CVRs for pal 4. Shares would convert to Xers and believers would now own a $1B company with the incentives to get it to $5B hence the massive grants the ceo of Xers just received. 2nd play is if Abbvie or JNJ outbid the offer with substantial CVR and all cash deal. Either way Edick left for a purpose. Deals are coming in and finalizing. Just my two cents. Something going to shake in March.
3 · Reply
Geo1313
Geo1313 Feb. 20 at 6:55 PM
$VTGN 🙏🚀🚀🚀
0 · Reply
Maissessap
Maissessap Feb. 20 at 3:15 PM
$VTGN https://www.investing.com/news/sec-filings/vistagen-therapeutics-announces-resignation-of-board-member-paul-edick-93CH-4516427
0 · Reply
Latest News on VTGN
Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

Feb 12, 2026, 7:44 PM EST - 11 days ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 12, 2026, 4:30 PM EST - 11 days ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Feb 9, 2026, 5:21 PM EST - 14 days ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 6, 2026, 9:52 AM EST - 17 days ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Feb 4, 2026, 8:30 AM EST - 19 days ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 29, 2026, 8:24 AM EST - 25 days ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 22, 2026, 10:45 AM EST - 4 weeks ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jan 16, 2026, 5:06 PM EST - 5 weeks ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 12:42 PM EST - 2 months ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 17, 2025, 8:30 AM EST - 2 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Nick Tressler as Chief Financial Officer

Dec 1, 2025, 8:30 AM EST - 3 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 26, 2025, 8:30 AM EST - 3 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Nov 18, 2025, 7:45 AM EST - 3 months ago

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Nov 13, 2025, 7:01 PM EST - 3 months ago

Vistagen Therapeutics, Inc. (VTGN) Q2 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 13, 2025, 4:30 PM EST - 3 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 10, 2025, 8:30 AM EST - 3 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 5, 2025, 8:30 AM EST - 3 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Nov 3, 2025, 8:30 AM EST - 4 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Vistagen Appoints Paul Edick to its Board of Directors

Oct 29, 2025, 8:30 AM EDT - 4 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Oct 16, 2025, 8:30 AM EDT - 4 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 8:30 AM EDT - 5 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Aug 8, 2025, 2:13 PM EDT - 7 months ago

Vistagen Therapeutics, Inc. (VTGN) Q1 2026 Earnings Call Transcript

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Aug 7, 2025, 4:30 PM EDT - 7 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 31, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 24, 2025, 8:30 AM EDT - 7 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jul 15, 2025, 8:30 AM EDT - 7 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 25, 2025, 8:30 AM EDT - 8 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Jun 17, 2025, 6:49 PM EDT - 8 months ago

Vistagen Therapeutics, Inc. (VTGN) Q4 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 17, 2025, 4:30 PM EDT - 8 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 12, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Jun 2, 2025, 8:30 AM EDT - 9 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 28, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Apr 17, 2025, 8:30 AM EDT - 11 months ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Feb 14, 2025, 6:19 PM EST - 1 year ago

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Feb 13, 2025, 8:47 PM EST - 1 year ago

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 13, 2025, 4:30 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Geo1313
Geo1313 Feb. 23 at 10:48 PM
$VTGN Because you are shorting it,thats what managment said.And also said that last time runned to$70 and burned losts of piuky shorts like you.
0 · Reply
CatchTheCleanUpSet
CatchTheCleanUpSet Feb. 23 at 7:43 PM
$VTGN so has management said anything about why the last trial failed ? And why 2 of the 3 trials failed but one did great ?
0 · Reply
smooth2222
smooth2222 Feb. 23 at 5:14 PM
$VTGN looks like .60 is our resistance.
1 · Reply
Geo1313
Geo1313 Feb. 23 at 7:25 AM
$VTGN Huge🚀🚀🚀
0 · Reply
Sinisoni
Sinisoni Feb. 23 at 12:51 AM
$VTGN bullish loading hard
1 · Reply
MakesHerSquirt
MakesHerSquirt Feb. 22 at 11:50 PM
$VTGN HAHA let's gamble ! 5x -10x! Who has the balls to play this high stakes game. THE HOUSE HAS THE ATVANTAGE!
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 21 at 3:49 PM
$VTGN
1 · Reply
mb0157
mb0157 Feb. 21 at 2:19 AM
$VTGN today’s news with Paul edick resignation is massive. He also dismissed his role at Xeris pharmacies Feb 1. No more conflict of interest. He’s known for creative deals so I can see two things possible. 1. Xers makes an all stock swap offer to Vtgn in March. $3-$4 range with CVRs for pal 4. Shares would convert to Xers and believers would now own a $1B company with the incentives to get it to $5B hence the massive grants the ceo of Xers just received. 2nd play is if Abbvie or JNJ outbid the offer with substantial CVR and all cash deal. Either way Edick left for a purpose. Deals are coming in and finalizing. Just my two cents. Something going to shake in March.
3 · Reply
Geo1313
Geo1313 Feb. 20 at 6:55 PM
$VTGN 🙏🚀🚀🚀
0 · Reply
Maissessap
Maissessap Feb. 20 at 3:15 PM
$VTGN https://www.investing.com/news/sec-filings/vistagen-therapeutics-announces-resignation-of-board-member-paul-edick-93CH-4516427
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 20 at 2:54 PM
$VTGN
0 · Reply
mb0157
mb0157 Feb. 20 at 2:37 PM
SEC Filing | Vistagen Therapeutics, Inc. $VTGN. Not sure yet how this plays out. Could be bearish as it’s such short stint. Or bullish of licensing deal is imminent and his job is done. https://www.vistagen.com/node/14636/html
1 · Reply
donemedirty
donemedirty Feb. 20 at 1:49 PM
$VTGN lets break .60
1 · Reply
Sinisoni
Sinisoni Feb. 19 at 11:50 PM
$VTGN bullish strong buy
0 · Reply
Geo1313
Geo1313 Feb. 19 at 10:33 PM
$VTGN $CTW $SMTK $NOTE
0 · Reply
To_De_Moon
To_De_Moon Feb. 19 at 8:47 PM
$VTGN keep up
0 · Reply
mb0157
mb0157 Feb. 19 at 8:46 PM
$VTGN. 2nd time in a week this name has turned up. Very good to see.
0 · Reply
nightstocker15
nightstocker15 Feb. 19 at 8:44 PM
$VTGN 💪
0 · Reply
ThaDankles
ThaDankles Feb. 19 at 8:24 PM
$VTGN the question is were you here before the news? Did you do your homework. Or will you see the 400% day and say dang I should have been there….? Let it be known who’s here early. $OLB $FEED $BYND
2 · Reply
ThaDankles
ThaDankles Feb. 19 at 8:15 PM
$VTGN this is the grandslam waiting to happen
0 · Reply
TinyTiger19
TinyTiger19 Feb. 19 at 7:27 PM
$VTGN $CTW $SMTK $NOTE …
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 19 at 4:13 PM
$VTGN
0 · Reply